About Zoetis Inc.
Zoetis Inc. (ZTS) is a Healthcare company in the Pharmaceutical Preparations industry with a market capitalisation of $30.5B. The stock trades at 12.02x trailing earnings and yields 2.86%.
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Market cap
- $30.5B
- P/E ratio
- 12.02
- EPS (TTM)
- $6.02
- Revenue (TTM)
- $9.5B
- Free cash flow
- $2.3B
- Profit margin
- 28.2%
- Dividend yield
- 2.86%
- Shares outstanding
- 413.2M
Financial health: Strong7.8/10
6 strengths, 1 concern. Weakest points: debt to equity.
- Debt to equity: 2.71 (Concern, benchmark < 0.5) — Debt of 2.71x equity is high against the 0.5x benchmark. It has deteriorated over the last 4 years.
- Net debt vs cash flow: 2.9y (Strong, benchmark < 4 years) — Net debt of $6.7B is 2.9x annual free cash flow — about 3 years of cash flow to repay.
- Current ratio: 3.03 (Strong, benchmark > 1.5) — Short-term assets cover 3.03x short-term liabilities, against Graham's 1.5x floor. It has improved over the last 4 years.
- Return on equity: 80.2% (Strong, benchmark > 15%) — Earns 80.2% on shareholder equity, comfortably past the > 15% mark.
- Gross margin: 71.5% (Strong, benchmark > 40%) — Keeps 71.5% of revenue after the direct cost of sales, comfortably past the > 40% mark.
- Net margin: 28.2% (Strong, benchmark > 10%) — Turns 28.2% of revenue into profit, comfortably past the > 10% mark.
- Free cash flow: $2.3B (Strong, benchmark positive) — Generated $2.3B of free cash flow after capital spending. It has improved over the last 4 years.
- Revenue growth: 2.3% (Watch, benchmark > 10%) — Revenue changed 2.3% year on year, short of the > 10% mark.
- Earnings growth: 7.5% (Watch, benchmark > 10%) — Earnings changed 7.5% year on year, short of the > 10% mark.